Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial-Reference-Cited by-同舟云学术

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

Published:2012-04 Issue:2 Volume:12 Page:81-86
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Tan Winston W.,Allred Jacob B.,Salim Muhammad,Flynn Patrick,Fishkin Paul A.S.,Stella Philip J.,Wiesenfeld Martin,Bernath Albert M.,Fitch Tom R.,Perez Edith A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer;Livingston;J Clin Oncol,1997

2. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy;Fumoleau;J Clin Oncol,1993

3. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer;Blum;J Clin Oncol,1999

4. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results;O'Shaughnessy;J Clin Oncol,2002

5. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer;Burstein;J Clin Oncol,2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis;Bioengineered;2021-12-11

2. Effect of capecitabine on breast cancer patients with different estrogen receptor status;BANGL J PHARMACOL;2020

3. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance);Clinical Cancer Research;2018-03-12

4. Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer;Chemotherapy;2016-09-21

5. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain;Cancer Research;2016-04-20